Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (35)
  • Open Access

    ARTICLE

    The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory

    MAHER KURDI1,*, ALAA ALKHOTANI2, ABDULRAHMAN SABBAGH3, EYAD FAIZO4, AHMED I. LARY5, AHMED K. BAMAGA6, MAJID ALMANSOURI7, BADR HAFIZ8, THAMER ALSHARIF9, SALEH BAEESA8

    Oncology Research, Vol.32, No.6, pp. 1037-1045, 2024, DOI:10.32604/or.2024.051112 - 23 May 2024

    Abstract Background: The dysregulation of Isocitrate dehydrogenase (IDH) and the subsequent production of 2-Hydroxyglutrate (2HG) may alter the expression of epigenetic proteins in Grade 4 astrocytoma. The interplay mechanism between IDH, O-6-methylguanine-DNA methyltransferase (MGMT)-promoter methylation, and protein methyltransferase proteins-5 (PRMT5) activity, with tumor progression has never been described. Methods: A retrospective cohort of 34 patients with G4 astrocytoma is classified into IDH-mutant and IDH-wildtype tumors. Both groups were tested for MGMT-promoter methylation and PRMT5 through methylation-specific and gene expression PCR analysis. Inter-cohort statistical significance was evaluated. Results: Both IDH-mutant WHO grade 4 astrocytomas (n = 22, 64.7%) and IDH-wildtype… More > Graphic Abstract

    The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory

  • Open Access

    REVIEW

    Targeting brain tumors with innovative nanocarriers: bridging the gap through the blood-brain barrier

    KARAN WADHWA1, PAYAL CHAUHAN1, SHOBHIT KUMAR2, RAKESH PAHWA3,*, RAVINDER VERMA4, RAJAT GOYAL5, GOVIND SINGH1, ARCHANA SHARMA6, NEHA RAO3, DEEPAK KAUSHIK1,*

    Oncology Research, Vol.32, No.5, pp. 877-897, 2024, DOI:10.32604/or.2024.047278 - 23 April 2024

    Abstract Background: Glioblastoma multiforme (GBM) is recognized as the most lethal and most highly invasive tumor. The high likelihood of treatment failure arises from the presence of the blood-brain barrier (BBB) and stem cells around GBM, which avert the entry of chemotherapeutic drugs into the tumor mass. Objective: Recently, several researchers have designed novel nanocarrier systems like liposomes, dendrimers, metallic nanoparticles, nanodiamonds, and nanorobot approaches, allowing drugs to infiltrate the BBB more efficiently, opening up innovative avenues to prevail over therapy problems and radiation therapy. Methods: Relevant literature for this manuscript has been collected from a comprehensive More > Graphic Abstract

    Targeting brain tumors with innovative nanocarriers: bridging the gap through the blood-brain barrier

  • Open Access

    REVIEW

    A review on potential heterocycles for the treatment of glioblastoma targeting receptor tyrosine kinases

    NILAM BHUSARE, MAUSHMI KUMAR*

    Oncology Research, Vol.32, No.5, pp. 849-875, 2024, DOI:10.32604/or.2024.047042 - 23 April 2024

    Abstract Glioblastoma, the most aggressive form of brain tumor, poses significant challenges in terms of treatment success and patient survival. Current treatment modalities for glioblastoma include radiation therapy, surgical intervention, and chemotherapy. Unfortunately, the median survival rate remains dishearteningly low at 12–15 months. One of the major obstacles in treating glioblastoma is the recurrence of tumors, making chemotherapy the primary approach for secondary glioma patients. However, the efficacy of drugs is hampered by the presence of the blood-brain barrier and multidrug resistance mechanisms. Consequently, considerable research efforts have been directed toward understanding the underlying signaling pathways… More > Graphic Abstract

    A review on potential heterocycles for the treatment of glioblastoma targeting receptor tyrosine kinases

  • Open Access

    ARTICLE

    GRIK1 promotes glioblastoma malignancy and is a novel prognostic factor of poor prognosis

    GUOQIANG HOU1,2,#, XINHANG XU2,#, WEIXING HU1,*

    Oncology Research, Vol.32, No.4, pp. 727-736, 2024, DOI:10.32604/or.2023.043391 - 20 March 2024

    Abstract Primary tumors of the central nervous system (CNS) are classified into over 100 different histological types. The most common type of glioma is derived from astrocytes, and the most invasive glioblastoma (WHO IV) accounts for over 57% of these tumors. Glioblastoma (GBM) is the most common and fatal tumor of the CNS, with strong growth and invasion capabilities, which makes complete surgical resection almost impossible. Despite various treatment methods such as surgery, radiotherapy, and chemotherapy, glioma is still an incurable disease, and the median survival time of patients with GBM is shorter than 15 months.… More >

  • Open Access

    REVIEW

    LncRNAs unraveling their sponge role in glioblastoma and potential therapeutic applications

    CAIJUAN LIU, XINGHAO LI, YUXUAN WU, JINHUI YANG, MENGHAN WANG, YUNQI MA*

    BIOCELL, Vol.48, No.3, pp. 387-401, 2024, DOI:10.32604/biocell.2024.048791 - 15 March 2024

    Abstract Glioblastoma multiforme (GBM), the most common and aggressive primary brain tumor in adults, is the most malignant and still has no cure. However, the novel role of long non-coding RNAs (lncRNAs) in the pathogenesis of glioblastoma is attracting extensive attention. LncRNAs are transcribed RNA molecules over 200 nucleotides long that do not encode proteins. Unlike small non-coding RNAs, such as microRNAs (miRNAs), lncRNAs have more complex secondary and tertiary structures that enable them to interact with DNA, RNA, and proteins and perform multiple regulatory functions. LncRNAs act as molecular sponges, absorbing and sequestering other biomolecules,… More > Graphic Abstract

    LncRNAs unraveling their sponge role in glioblastoma and potential therapeutic applications

  • Open Access

    REVIEW

    Stem cell technology for antitumor drug loading and delivery in oncology

    FRANCESCO PETRELLA*, ENRICO MARIO CASSINA, LIDIA LIBRETTI, EMANUELE PIRONDINI, FEDERICO RAVEGLIA, ANTONIO TUORO

    Oncology Research, Vol.32, No.3, pp. 433-437, 2024, DOI:10.32604/or.2023.046497 - 06 February 2024

    Abstract The main aim of antineoplastic treatment is to maximize patient benefit by augmenting the drug accumulation within affected organs and tissues, thus incrementing drug effects and, at the same time, reducing the damage of non-involved tissues to cytotoxic agents. Mesenchymal stromal cells (MSC) represent a group of undifferentiated multipotent cells presenting wide self-renewal features and the capacity to differentiate into an assortment of mesenchymal family cells. During the last year, they have been proposed as natural carriers for the selective release of antitumor drugs to malignant cells, thus optimizing cytotoxic action on cancer cells, while More >

  • Open Access

    ARTICLE

    Long non-coding RNA DPP10-AS1 represses the proliferation and invasiveness of glioblastoma by regulating miR-24-3p/CHD5 signaling pathway

    JIWEI SUN1,2,#, LIANG XU1,#, YESEN ZHANG2, HAORAN LI1, JIE FENG2, XUEFENG LU2, JUN DONG1,*

    BIOCELL, Vol.47, No.12, pp. 2721-2733, 2023, DOI:10.32604/biocell.2023.043869 - 27 December 2023

    Abstract Objective: This investigation aimed to unveil new prospective diagnosis-related biomarkers together with treatment targets against glioblastoma. Methods: The expression levels of long non-coding RNA (lncRNA) DPP10-AS1 were assessed using real-time quantitative polymerase chain reaction (RT-qPCR) within both the patient tissue specimens and glioblastoma cell lines. The relationship between lncRNA DPP10-AS1 expression in glioblastoma and patient prognosis was investigated. Cell Counting Kit-8 (CCK-8), transwell, and clonogenic experiments were utilized to assess tumor cells’ proliferation, invasiveness, and migratory potentials after lncRNA DPP10-AS1 expression was up or down-regulated. Using an online bioinformatics prediction tool, the intracellular localization of lncRNA… More >

  • Open Access

    ARTICLE

    UCHL5 inhibits U251 glioma cell proliferation and tumor growth via stabilizing and deubiquitinating PTEN

    YUE XIAO1,2,#, WENJING MA2,#, XINYI CHEN2, WEIWEI HU3, QIANQIAN DI2, XIBAO ZHAO2, GUODONG HUANG1, WEILIN CHEN1,2,*

    BIOCELL, Vol.47, No.12, pp. 2617-2625, 2023, DOI:10.32604/biocell.2023.042476 - 27 December 2023

    Abstract Background: Glioma is the most common primary brain tumor. Exploration of new tumorigenesis mechanism of glioma is critical to determine more effective treatment targets as well as to develop effective prognosis methods that can enhance the treatment efficacy. We previously demonstrated that the deubiquitinase biquitin carboxyl-terminal hydrolase L5 (UCHL5) was downregulated in human glioma. However, the effect and mechanism of UCHL5 on the proliferation of glioma cells remains unknown. Methods: Transfection of siRNA was used to knockdown the expression of UCHL5 in U251 cells. The 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay, Edu assay, and colony formation… More > Graphic Abstract

    UCHL5 inhibits U251 glioma cell proliferation and tumor growth via stabilizing and deubiquitinating PTEN

  • Open Access

    ARTICLE

    CHRM3 is a novel prognostic factor of poor prognosis and promotes glioblastoma progression via activation of oncogenic invasive growth factors

    BIN ZHANG1,#, JIANYI ZHAO3,#, YONGZHI WANG2,#, HUA XU1, BO GAO1, GUANGNING ZHANG1, BIN HAN1, GUOHONG SONG1, JUNCHEN ZHANG1,*, WEI MENG1,*

    Oncology Research, Vol.31, No.6, pp. 917-927, 2023, DOI:10.32604/or.2023.030425 - 15 September 2023

    Abstract Glioblastoma (GBM) is the most aggressive cancer of the brain and has a high mortality rate due to the lack of effective treatment strategy. Clarification of molecular mechanisms of GBM’s characteristic invasive growth are urgently needed to improve the poor prognosis. Single-nuclear sequencing of primary and recurrent GBM samples revealed that levels of M3 muscarinic acetylcholine receptor (CHRM3) were significantly higher in the recurrent samples than in the primary samples. Moreover, immunohistochemical staining of an array of GBM samples showed that high levels of CHRM3 correlated with poor prognosis, consistent with The Cancer Genome Atlas More >

  • Open Access

    REVIEW

    Underlying mechanisms and clinical potential of circRNAs in glioblastoma

    LEI ZHANG*, YUAN ZHANG, HUIJUAN GAO, XIN LI, PEIFENG LI*

    Oncology Research, Vol.31, No.4, pp. 449-462, 2023, DOI:10.32604/or.2023.029062 - 25 June 2023

    Abstract Glioblastoma (GBM) is the most malignant form of glioma and is difficult to diagnose, leading to high mortality rates. Circular RNAs (circRNAs) are noncoding RNAs with a covalently closed loop structure. CircRNAs are involved in various pathological processes and have been revealed to be important regulators of GBM pathogenesis. CircRNAs exert their biological effects by 4 different mechanisms: serving as sponges of microRNAs (miRNAs), serving as sponges of RNA binding proteins (RBPs), modulating parental gene transcription, and encoding functional proteins. Among the 4 mechanisms, sponging miRNAs is predominant. Their good stability, broad distribution and high More > Graphic Abstract

    Underlying mechanisms and clinical potential of circRNAs in glioblastoma

Displaying 11-20 on page 2 of 35. Per Page